All News

The study results also showed that older age was significantly associated with lower cancer genetics knowledge, which, according to a post-doctoral research fellow at Dana-Farber Cancer Institute, is important because older adults may serve as a resource for family members who seek information about their family's health history.

Cancer survivors sometimes wonder about their purpose on earth as time passes and so many others pass away before us with cancer. We need to be gentle with ourselves and not stress to much.

From the passing of famed Game of Thrones actress Dame Dianna Rigg after a lung cancer diagnosis to the recording of a confrontational call between a three-time cancer survivor and her senator’s staffer, here’s what’s happening in the cancer headlines this week.

Forty percent of patients with triple-refractory multiple myeloma achieved a response after receiving 60 millicurie (a unit of radioactivity) or greater of CLR 131.

Compared to physician’s choice of chemotherapy, the MEK inhibitor Mektovi failed to improve progression-free survival in patients with low-grade serous ovarian carcinomas. However, the study authors note Mektovi demonstrated promising results that support continued use of the treatment.

When compared with the standard of care triplet regimen of Velcade, Revlimid and dexamethasone, the combination of Kyprolis, Revlimid and dexamethasone did not demonstrate superior treatment results in patients with newly diagnosed multiple myeloma.

I received a phone call that would alter the course of my life in ways that I couldn’t possibly have imagined. On the other end was my 27-year-old daughter and I sat dazed and confused as she tearfully said, “Mom … it’s cancer.”

Adding Venclexta to Vidaza chemotherapy improved survival and boosted the complete remission rate in previously untreated patients with AML who had coexisting health conditions and/or were age 75 or older, results from a phase 3 clinical trial showed.

Supportive and palliative care are critical for people living with cancer to better manage treatment-related side effects.

The FDA based its decision on data from a phase 3 trial which showed that adding plinabulin to Neulasta significantly improved the rate of severe chemotherapy-induced neutropenia.

There have been several drug approvals and updates from the Food and Drug Administration (FDA) in the cancer space over the last several weeks.

The Food and Drug Administration’s warning comes weeks after Genentech, the manufacturer of Tecentriq, issued a press release noting that the IMpassion131 trial failed to meet its primary endpoint of improving progression-free survival in patients with triple-negative breast cancer.

“Our hope is that this will enable us to reduce or eliminate late effects of treatment that persist into the survivorship years,” Dr. Peter Cole, of Rutgers Cancer Institute of New Jersey, said in a press release.

An author and two-time cancer survivor offers fellow writers some advice on what they’ll need to know if they’re considering writing a book about surviving cancer.

On social media, CURE® recently asked its readers to share the most surprising thing that’s changed in their life since receiving a cancer diagnosis. Here, we share some of their responses.

The day cancer treatment ends, a new chapter begins. Some survivors may leave cancer behind and continue life with few or no health problems. Others might have ongoing physical challenges. Some of these might be due to late effects (also called aftereffects) of cancer treatment.

A roundup of the latest news and updates for patients with metastatic breast cancer from CURE®.

The relationship that develops between a cancer patient and their oncology team is a most intimate thing.

Like the novel coronavirus, cancer is invisible, unrelenting, and always surrounding us.

Throughout the summer, CURE® highlighted many simple and healthy recipes that the oncology dietitians from the John Theurer Cancer Center put together for cancer survivors and patients. Here, we share some of those recipes.

A pancreatic cancer survivor offers other patients tips he has learned along his journey to help them get through their treatments.

A roundup of the latest news and updates for patients with prostate cancer from CURE®.

The Food and Drug Administration approves Gavreto for treatment of patients with metastatic, RET fusion-positive non-small cell lung cancer.

A recent approval of the combination of Monjuvi and Revlimid fills an unmet need for certain patients with DLBCL, according to Dr. Gilles Salles.

Patients with cancer have a right to choose not to treat their illness, even if it’s not a popular decision.

From researchers identifying honeybee venom’s potential to kill cancer cells in a lab to a new study showing cancer risk was not significantly associated with use of permanent hair dye in women, here’s what’s happening in the cancer landscape this week.

The Food and Drug Administration granted a priority review to the new drug application for melflufen in combination with dexamethasone for adults with relapsed and refractory multiple myeloma (RRMM) who had previously received multiple lines of therapy.

Allogeneic hematopoietic stem cell transplant’s role in the chronic lymphocytic leukemia has changed due to new novel agents, but research shows its still effective despite novel agent exposure.

Immediate treatment with Lynparza after standard surgery and chemotherapy should be considered for all patients with newly diagnosed stage 3 or 4 ovarian cancer that carries a BRCA gene mutation, even if residual disease remains, researchers have found.

It seems acceptable in our world to grieve the loss of a loved one, but unheard of to grieve the loss of body parts.